BLK and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib, utilized to inhibit BLK both in this study and in previous works, has been approved by the FDA for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [36, 49–51].